Board approves unaudited Q2 and H1 results; auditor's review conclusion unmodified
Board met on October 16, 2026 and approved the unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 417.34 | 313.54 | +33.1% | 381.60 | +9.4% |
| Total income | 417.88 | 314.03 | +33.1% | 384.29 | +8.7% |
| Profit before tax | 28.46 | (10.10) | — | 16.31 | +74.5% |
| Profit after tax | 28.46 | (10.10) | — | 16.31 | +74.5% |
| Total comprehensive income | 28.59 | (9.29) | — | 16.26 | +75.8% |
| Basic EPS | 5.92 | (2.36) | — | 3.52 | +68.2% |
- Total Income YoY Change
- +33.1% (Year ago 314.03)
- Profit After Tax (Latest)
- 28.46 (Year ago (10.10), Prev qtr 16.31, +74.5%)
- Period
- 3 months ended 30.09.2026
Auditor's review
Conclusion: Unmodified
Notes to the results
- Exceptional item: loss of Rs. (4.50) crores on sale of capital work in progress relating to Vizag plant, mothballed since FY 2023-24, in quarter ended 30.09.2026.
- Group has accumulated losses of Rs. 274.16 crores as of September 30, 2026 (March 31, 2026: Rs. 319.33 crores); results prepared on a going concern basis.
- Rights issue: Rs. 446.62 crores raised of Rs. 449.95 crores; Rs. 133.09 crores received against final call made on May 7, 2026 (Rs. 1.90 crores unpaid).
- In-principle approval (Jan 24, 2025) to explore demerger of CRAMS and Polymers business; Synthix Global Pharma Solutions Limited incorporated on April 29, 2025.
Outcome of the board meeting
The Board of Directors met on October 16, 2026 and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the limited review report of the statutory auditor.
Review conclusion
Deloitte Haskins & Sells LLP, the statutory auditor, reviewed both the consolidated and the standalone results and issued an unmodified conclusion. A limited review is narrower in scope than a full audit and is not an audit opinion.
Consolidated numbers for the quarter
- Revenue from operations: Rs. 417.34 crore
- Profit after tax: Rs. 28.46 crore, compared with a loss of Rs. 10.10 crore in the same quarter a year earlier
Exceptional item
- The consolidated result carries an exceptional item: a loss of Rs. 4.50 crore on sale of capital work in progress relating to the Vizag plant.
Half year and balance sheet position
- Total income for the half year (consolidated): Rs. 802.17 crore
- Accumulated losses as at September 30, 2026: Rs. 274.16 crore
- Management states that improvement in business performance, anticipated growth in revenues and margins, expected renewal of working capital facilities and projected cash flows should give the group adequate resources to meet its obligations as they fall due, and the consolidated results are prepared on a going concern basis.
Other notes in the update
- The Board had earlier discussed a proposal to explore demerger of the CRAMS and Polymers business into an independent listed entity and granted in-principle approval for the same; Synthix Global Pharma Solutions Limited was incorporated as a wholly owned subsidiary for this.
- The registration of the Brazil subsidiary was cancelled.
- The rights issue had offered 1,19,98,755 equity shares, aggregating Rs. 449.95 crore.
Points to note
- The quarter shows a profit against a loss in the same quarter a year earlier, while accumulated losses and the going concern note remain part of the same disclosure. Investors can track whether the improvement in performance continues in the coming quarters.
Also from Solara Active Pharma Sciences
Q2 FY27 call: revenue up 33% to INR418 crores, PAT INR28.5 crores; Ibuprofen review to close in 12 weeks
23 Oct 2026
Final reminder-cum-forfeiture notice sent to holders of partly paid-up shares
17 Oct 2026
Monitoring Agency Report: no deviation in Rights Issue proceeds utilisation
16 Oct 2026
More numbers
- Consolidated Total income, half year ended Sept 30, 2026 (Rs. in crore)802.17
- Accumulated losses as at September 30, 2026Rs. 274.16 crores
- Exceptional item: loss on sale of capital work in progress, Vizag plantRs. 4.50 crores
- Rights issue sizeRs. 449.95 crores
- Equity shares offered in the rights issue1,19,98,755
- Total income, latest quarter417.88 (Rs. In Crores)
- Total income, year-ago quarter314.03 (Rs. In Crores)
- Total income, previous quarter384.29 (Rs. In Crores)
- Total comprehensive income, latest quarter28.59 (Rs. In Crores)
- Total comprehensive income, year-ago quarter(9.29) (Rs. In Crores)
- Total comprehensive income, previous quarter16.26 (Rs. In Crores)
- Profit after tax, latest quarter28.46 (Rs. In Crores)
- Profit after tax, year-ago quarter(10.10) (Rs. In Crores)
- Profit after tax, previous quarter16.31 (Rs. In Crores)
- Revenue from operations, latest quarter417.34 (Rs. In Crores)
- Revenue from operations, year-ago quarter313.54 (Rs. In Crores)
- Revenue from operations, previous quarter381.60 (Rs. In Crores)
- Profit before tax, latest quarter28.46 (Rs. In Crores)
- Profit before tax, year-ago quarter(10.10) (Rs. In Crores)
- Profit before tax, previous quarter16.31 (Rs. In Crores)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.